Aethlon Medical

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Aethlon Medical Advances Hemopurifier, Eyes Clinical Trials

Aethlon Medical is poised for pivotal clinical trials in Australia, focusing on its Hemopurifier technology's application in cancer treatment. Financially, the company has maintained a stable cash flow, managing a modest increase in expenses. The upcoming trials and potential expansion into the organ transplant sector highlight promising growth areas.

Aethlon Medical reports financial progress and global trial expansions

Aethlon Medical's Q1 2025 earnings call highlighted financial improvements, progress in Hemopurifier research, and global clinical trial expansions.
While challenges like expense projections and trial paperwork exist, opportunities in therapy enhancement and market expansion are promising for Aethlon.
The company's commitment to innovation, financial efficiency, and stakeholder communication bodes well for its future growth and success.
Investors can find confidence in Aethlon's strategic focus on advancing therapies and expanding its global reach in the oncology space.

Aethlon Medical reports strong Q2 performance amidst oncology trial progress

Aethlon Medical's Q2 2025 performance showcased financial stability, progress in oncology trials, and strategic cost reductions.
While challenges like trial complexities and data management exist, the company's strengths in innovation and transparency offer growth opportunities.
Navigating operational challenges and leveraging trial successes can drive Aethlon's long-term success in the healthcare industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , June 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Charles J. Fisher, Jr. M.D.

Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest

SAN DIEGO , June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT. Management will also be participating in one-on-one meetings with investors at this conference being held June 6-8, 2023, in Los Angeles, California.

Aethlon Medical to Present at the 13th Annual LD Micro Invitational

SAN DIEGO , May 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier® to treat severe COVID-19 in India. MAMC was established in 1958 and is located in New Delhi, India.

Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India

Mangoceuticals Inc

Nordic American Tankers

Onconova Therapeutics

Tingo Group Inc

Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.

5 Hot Penny Stocks To Watch With The Stock Market Down This Week

CNS Pharmaceuticals

Getaround Inc

Use these tips for trading penny stocks efficiently The post Essential Penny Stock Trading Tools: Maximizing Efficiency appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Essential Penny Stock Trading Tools: Maximizing Efficiency

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Jim Frakes - Chief Financial Officer Steven LaRosa - Chief Medical Officer Guy Cipriani - Chief Business Officer Conference Call Participants Marla Marin - Zacks Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2023 Earnings and Corporate Update Call. All participants will be in listen-only mode.

Aethlon Medical, Inc. (AEMD) Q3 2023 Earnings Call Transcript

SAN DIEGO , Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier ®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood.

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 6, 2023.

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023

Presentation on Thursday, February 2nd, 2023 at 10:00 AM ET SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease,  announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D.

Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023

G Medical Innovations Holdings Ltd

Heart Test Laboratories Inc

Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Using Technical Indicators to Find Penny Stocks to Buy

It's not every day that Aethlon Medical (NASDAQ: AEMD ) gets this much attention. AEMD stock is soaring today on unusually high volume.

Why Is Aethlon Medical (AEMD) Stock Up 50% Today?

SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications. Pursuant to the agreement, NAMSA will manage Aethlon's study of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors.

Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Fisher - Chief Executive Officer James Frakes - Senior Vice President and Chief Financial Officer Steven LaRosa - Chief Medical Officer Guy Cipriani - Senior Vice President and Chief Business Officer Conference Call Participants Marla Marin - Zacks Investment Research Thomas McGovern - Maxim Group Operator Good afternoon and welcome to the Aethlon Medical's Second Quarter Fiscal 2022 Earnings and Corporate Update Conference Call. Participants will be in listen-only mode.

Aethlon Medical, Inc. (AEMD) Q2 2022 Earnings Call Transcript

SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood.

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022

SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that it will be presenting at two investor conferences in September.

Aethlon Medical to Present at Two Investor Conferences in September

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2023 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Chuck Fisher - CEO Jim Frakes - CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Hello, and welcome to the Aethlon First Quarter Fiscal 2023 Earnings and Corporate Update Conference Call. All participants will be in listen-only mode.

Aethlon Medical, Inc.'s (AEMD) CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove life-threatening viruses and harmful exosomes from blood.

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Applied DNA Sciences

Chembio Diagnostics

E-Home Household Service Holdings Ltd

NanoViricides

SIGA Technologies

Tonix Pharmaceuticals Hld

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022

Here's what you need to know about buying penny stocks today The post Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch

Monkeypox penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 Monkeypox Stocks To Watch This Week

SAN DIEGO , July 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced the publication of a peer-reviewed journal article in PLOS ONE. The article, titled "Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin," contains data demonstrating that the proprietary GNA affinity resin of the Aethlon Hemopurifier® efficiently captures seven clinically relevant variants of the SARS-CoV-2 virus responsible for the COVID-19 pandemic.

Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants

Assertio Therapeutics Inc

Helix Energy Solutions Group

Transocean

Are you looking for some hot penny stocks to buy this week?

Hot Penny Stocks To Buy? 4 Under $3 To Watch This Week

Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study SAN DIEGO , July 11, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening.

News for Aethlon Medical Stock (AEMD)